MiNK Therapeutics (NASDAQ:INKT – Get Free Report) announced its earnings results on Tuesday. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.12), Zacks reports.
MiNK Therapeutics Stock Down 3.3 %
NASDAQ:INKT opened at $8.24 on Wednesday. MiNK Therapeutics has a twelve month low of $4.56 and a twelve month high of $19.00. The firm has a market capitalization of $32.66 million, a price-to-earnings ratio of -2.11 and a beta of 0.16. The stock’s 50 day moving average price is $8.91 and its two-hundred day moving average price is $7.75.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reissued a “buy” rating and issued a $35.00 price target on shares of MiNK Therapeutics in a research note on Tuesday.
About MiNK Therapeutics
MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.
Read More
- Five stocks we like better than MiNK Therapeutics
- 5 discounted opportunities for dividend growth investors
- 3 Stocks Returning Billions to Shareholders via Buybacks
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Tesla: 1 Reason to Love It, 1 Reason to Be Cautious
- What is a penny stock? A comprehensive guide
- 3 Stocks That Could Win Big From a 10% Cap on Credit Card Rates
Receive News & Ratings for MiNK Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiNK Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
